Skip to main content
. 2021 Aug 11;39(38):5337–5340. doi: 10.1016/j.vaccine.2021.08.025

Table 1.

Baseline characteristics.

All
(n = 116)
Age ≥ 50
(n = 68)
Age < 50
(n = 48)
Age y (mean [±SD]) 50.3 (11.0) 57.9 (5.0) 39.6 (7.6)
Sex, male (%) 9 (7.8%) 5 (7.4%) 4 (8.3%)
Serology tests, n (mean [±SD]) 3.3 (1.7) 3.3 (1.7) 3.3 (1.7)
Days between vaccine doses (mean [±SD]) 21.5 (1.0) 21.3 (0.8) 21.7 (1.1)

3 individuals had not yet been eligible to receive the second dose of BNT162b2 by the time of data analysis. Two of these are older than 50.